← All diseases Rare and hereditary disorders

Hereditary ATTR amyloidosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest quality evidence only (79)Meta-analysis (11)Treatment guideline (1)Phase 3 study (29)Randomized trial (23)Systematic review (15)Clinical trial (345)Review article (146)Early study (phase 1 or 2) (7)Case report (135)Laboratory or animal study (8)Commentary or editorial (72) Studies currently recruiting participants only (34)

Filter

Publications and studies (1285)

• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Assessment of 18F-Florbetaben Whole-body PET for the Detection of Cardiac and Extracardiac Sites of Amyloid Deposits (2025-02-11) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation (2025-02-07) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy (2025-02-03) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis (2025-01-31) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. MECKI-Amyloidosis: Assessment of the Exercise Capacity and Prognosis of Patients with Cardiac Amyloidosis (2025-01-29) ♡
• Orthogonal and multiplexable genetic perturbations with an engineered prime editor and a diverse RNA array. (2024/12/30) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. From Molecular to Radionuclide and Pharmacological Aspects in Transthyretin Cardiac Amyloidosis. (2024/12/27) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Prospective Multicenter Screening With High-Sensitivity Cardiac Troponin T for Wild-Type Transthyretin Cardiac Amyloidosis in Outpatient and Community-Based Settings. (2024/12/25) ♡
• Cluster analysis and analysis of risk factors for hereditary transthyretin amyloidosis cardiomyopathy. (2024/12/24) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical differential factors in patients with hereditary transthyretin amyloidosis with Val142Ile and Ser43Asn mutations. (2024/12/20) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Sustained Ventricular Tachycardia as the first presentation of transthyretin amyloid cardiomyopathy. (2024/12/13) ♡
• Management of Hereditary Transthyretin Amyloidosis (ATTRv) Patients and Asymptomatic Carriers in Spain: The EMPATIa Study. (2024/12/13) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. (2024/12/12) ♡
• Arginine: A potential prophylactic supplement for transthyretin amyloidosis. (2024/12/10) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A 68-Year-Old Colombian Man Presenting with Heart Failure and a Diagnosis of Cardiac Transthyretin Amyloidosis. (2024/12/09) ♡
• A Comparative Study of the Electroneurographic Findings in Amyloidotic Polyneuropathy in Patients with Light-Chain Amyloidosis and Glu54Gln Transthyretin Amyloidosis. (2024/12/09) ♡
• ATTRv-V30M amyloid fibrils from heart and nerves exhibit structural homogeneity. (2024/12/05) ♡
• Global longitudinal strain in pre-symptomatic patients with mutation for transthyretin amyloidosis. (2024/12/05) ♡
• Does the structure of transthyretin amyloid fibrils vary depending on the organ of accumulation? (2024/12/05) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Hereditary Transthyretin Amyloidosis in Patients Referred to a Genetic Testing Program. (2024/12/03) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Improving Health Equity Through Standardization and Selective Expansion of Genetic Testing in Transthyretin Amyloidosis. (2024/12/03) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Rare case of wtTTR amyloidosis and MGUS in a patient with lung adenocarcinoma. (2024/12/02) ♡
• Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis - correlation between neurofilament light chain and nerve conduction study. (2024/12/01) ♡
• Single-photon emission computed tomography/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis. (2024/12/01) ♡
• Distinguishing hypertensive cardiomyopathy from cardiac amyloidosis in hypertensive patients with heart failure: a CMR study with histological confirmation. (2024/12/01) ♡
• Neck triangle nerve enlargement in hereditary transthyretin amyloidosis correlates with changes in the autonomic, cardiac, and gastrointestinal systems. (2024/12/01) ♡
• Incidence and predictors of sudden death in patients with cardiac amyloidosis. (2024/12/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction. (2024/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Wild-Type Transthyretin Amyloidosis With 99mTc-PYP Uptake in the Extracardiac Soft Tissues But Not in the Myocardium. (2024/12/01) ♡
• Transthyretin cardiac amyloidosis patients in internal medicine: a 10-year retrospective study. (2024/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Phenotype variability and therapeutic response to Patisiran in patients with hereditary transthyretin amyloidosis: a Belgian real-world experience. (2024/12/01) ♡
• Rare transthyretin gene variants (p.Ala45Thr, p.Val91Ala, p.Phe53Cys, p.Ala101Val, p.Glu109Lys, and p.Phe53Leu): diagnostic pitfalls and clinical characteristics of Polish patients with transthyretin cardiac amyloidosis. (2024/11/28) ♡
• Divergent Total Synthesis of Isoflavone Natural Products and Their Potential as Therapeutic Agents for TTR Amyloidosis. (2024/11/22) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. TTR associated leptomeningeal amyloidosis in a Sri Lankan patient. (2024/11/15) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Cardiac amyloidosis. (2024/11/14) ♡
• Hereditary Transthyretin Amyloidosis Neuropathy with Intracellular Amyloidosis and Inclusions. (2024/11/11) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Spectrum of hereditary transthyretin amyloidosis due to T60A(p.Thr80Ala) variant in an Irish Amyloidosis Network. (2024/11/11) ♡
• The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement. (2024/11/08) ♡
• Elucidation of the mechanism of amyloid A and transthyretin formation using mass spectrometry-based absolute quantification. (2024/11/01) ♡
• [Amyloidosis - The pathologist's perspective]. (2024/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Clinical aspects of systemic amyloidosis in 2024]. (2024/11/01) ♡
• Improving genetic testing pathways for transthyretin amyloidosis in France: challenges and strategies. (2024/10/29) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Heart Failure with Preserved Ejection Fraction and Cardiac Amyloidosis in the Aging Heart. (2024/10/26) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Experience of Hereditary Amyloidosis with Rare Variant in Ecuador: Case Reports. (2024/10/21) ♡
• A series of cases of transthyretin amyloid cardiomyopathy with negative bone scintigraphy but a confirmed positive endomyocardial biopsy. (2024/10/15) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Familial NTCPD presenting with persistent hypercholanemia and co-existing with a series of novel heterozygous mutations. (2024/10/01) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. (2024/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Transthyretin Amyloidosis: Role of oxidative stress and the beneficial implications of antioxidants and nutraceutical supplementation. (2024/10/01) ♡
• Improved Access to Genetics Care is Needed to Address Health Inequities in ATTRv Amyloidosis. (2024/10/01) ♡
• Transthyretin amyloidosis prevalence and characteristics in Korean patients with heart failure with preserved or mildly reduced ejection fractions. (2024/10/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.